Cargando…
Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation
Lung cancer is still the main cause of cancer-related deaths worldwide, with most patients present with advanced disease and poor long-term prognosis. The aim of lung cancer treatment is to slow down the progression of the disease, to relieve the patients from the lung cancer symptoms and whenever p...
Autores principales: | Nurwidya, Fariz, Takahashi, Fumiyuki, Takahashi, Kazuhisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934098/ https://www.ncbi.nlm.nih.gov/pubmed/27433059 http://dx.doi.org/10.4103/0976-9668.184695 |
Ejemplares similares
-
Hypoxia Increases Gefitinib-Resistant Lung Cancer Stem Cells through the Activation of Insulin-Like Growth Factor 1 Receptor
por: Murakami, Akiko, et al.
Publicado: (2014) -
Epithelial Mesenchymal Transition in Drug Resistance and Metastasis of Lung Cancer
por: Nurwidya, Fariz, et al.
Publicado: (2012) -
Molecular Mechanisms Contributing to Resistance to Tyrosine Kinase-Targeted Therapy for Non-Small Cell Lung Cancer
por: Nurwidya, Fariz, et al.
Publicado: (2012) -
From tumor hypoxia to cancer progression: the implications of hypoxia-inducible factor-1 expression in cancers
por: Nurwidya, Fariz, et al.
Publicado: (2012) -
Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?
por: Joshi, Amit, et al.
Publicado: (2018)